Table 2.

Multivariable model for the risk of recurrence prediction

Predictor		β	SE(P)	HR (95% CI)	P-value	Risk points (max. 100)
Histotype	Squamous cell			Reference		0
	Adenocarcinoma	0.342	0.116	1.408 (1.120; 1.771)	0.003	7
	Adenosquamous	0.598	0.164	1.819 (1.317; 2.513)	< 0.001	11
	Neuroendocrine	1.741	0.246	5.704 (3.514; 9.260)	< 0.001	33
	Other	1.145	0.270	3.144 (1.848; 5.349)	< 0.001	22
Tumour diameter	< 0.5 cm			Reference		0
	0.5–1.99 cm	0.501	0.237	1.651 (1.035; 2.634)	0.035	10
	2–3.99 cm	1.115	0.236	3.051 (1.915; 4.858)	< 0.001	21
	≥ 4 cm	1.556	0.245	4.738 (2.925; 7.674)	< 0.001	30
Grade	1			Reference		0
	2	0.260	0.214	1.297 (0.852; 1.976)	0.235	5
	3	0.457	0.247	1.579 (0.970; 2.570)	0.085	9
Positive pelvic LN	0 / not assessed			Reference		0
	1	0.255	0.154	1.291 (0.953; 1.748)	0.098	5
	2	0.482	0.170	1.619 (1.158; 2.264)	0.005	9
	≥ 3	0.939	0.144	2.557 (1.927; 3.394)	< 0.001	18
LVSI	No / not assessed			Reference		0
	Yes	0.538	0.106	1.713 (1.390; 2.111)	< 0.001	10

β: beta coefficient; CI: confidence interval; LN: lymph node; LVSI: lymphovascular space invasion; SE: standard error.